0001628280-26-028744
SEC filingRevenue grew 7.8% to $311.3M, driven by AEC segment volume, but operating income fell 10.2% to $25.4M due to MC product mix and higher SG&A.
Despite pricing and demand pressures on revenue growth, the MC segment is expected to improve earnings through technological innovations, manufacturing productivity efficiencies, and cost controls. Publication grade paper demand is expected to continue declining through 2026 and beyond, offset by growing demand for tissue grade products. The AEC segment is anticipated to maintain its growth trajectory supported by program activity. The company remains focused on managing costs and capital allocation to navigate the mixed demand environment.